chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Gait disturbance in right leg where shot was administered, fever of 102, after motrin fever reduced to 100. Pain in right leg where shot was given and child not wanting to walk.
Nausea, headaches, chills, fever, body aches, fatigue, injection site pain. Dizziness (unsure if from vaccine or not)
Swelling at injection site. Rash to body. Fever 10 101.8. Aches, wheezing, chills.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40-year-old male patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: Z-PAK, start date: 17Jul2022, stop date: 23Jul2022.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) positive, notes: COVID 19 Treatment; (unspecified date) Negative, notes: Tested negative for covid after completing Paxlovid; (24Jul2022) positive, notes: then tested positive for covid on 8th day. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Broke out all over in a papular red rash, the next day. Seen today, 10 days later, and rash is still present over entire body.
"Developed left shoulder pain at the flu shot site few days after the flu vaccination. Then 2 days later, developed limitation in the range of motion of the left arm and left shoulder, then noticed the large hematoma at the site where the flu shot was given. Also noticed tingling in my small and ring fingers."
Patient stated that she was having flu like symptoms and fever with the second dose (was day 3). She also stated that she had flu like symptoms after her first dose for 10 days. As of our phone conversation her symptoms had not subsided (day 3). She did state that they appeared to be slightly more mild but not much.
Currently breastfeeding and had first period after vaginal delivery being heavier than usual, prior to vaccine the period lasted 1 day heavy, this time is going on for 3 days of heavy bleeding non-stop.  Haven?t visited doctor yet.
Patient presented to BWH ED on 8/21/21 with intermittent fevers, hypoxia, and hypotension found to be covid 19  positive with possible RLL aspiration pneumonia as well. Patient was fully vaccinated for covid.  Patient was treated for covid and was also given antibiotics given immunosuppression and concern for RLL PNA superinfection.  Patient developed worsening oxygen requirement times which were treated appropriately. Patient was discharged on 9/17/21.
Initial unsolicited case received from a health care professional on 14 April 2015. A female patient (confidential), whose medical history and concomitant medications were not reported, had received a dose of Influenza Vaccine (batch number, route and site of administration were not reported) on unspecified date. On unspecified date, the patient experienced a severe reaction, swollen throat and anaphylactic shock and died while using the vaccine. Laboratory investigations and corrective treatments were not reported. At the time of this report, the outcome of the events was fatal. Documents held by sender: None.
Upon internal review, a significant correction was performed on 08 December 2014 to change the coding of the event congestion from 'unevaluable event' to 'nasal congestion'. Initial report received from a healthcare professional on 17 Sep 2014. A female patient, whose age, medical history and concomitant medications were not reported, had received an intramuscular dose of FLUZONE QIV (lot number: UI158AA, dose, dose number, site of vaccination not reported) on 15 Sep 2014. It was reported that, on 16 Sep 2014, the patient felt achy, had congestion and experienced slight fever. Lab investigation details and corrective treatment were not reported. The outcome of the event was reported as unknown. Documents held by sender: None. Follow-up information received from healthcare professional on 12 November 2014. It was reported that the patient was no longer employed by the company. And it was unable to provide answers for the question. Hence end of follow-up. List of documents held by sender: none. Addendum on 08 December 2014: Upon internal review, a significant correction was performed to change the coding of the event congestion from 'unevaluable event' to 'nasal congestion'.
This is a 61y.o. female with PMH significant for RA and emphysema with home O2 use at 2LNC presents to ED with c/o coronavirus concern. Pt has been feeling fatigued with progressive worsening x 7 days. Pt states she is unable to complete her ADLs without feeling SOB and tired which is not normal for her. Associated symptoms include cough with scant clear sputum production, wheezing, decreased appetite, and nausea without vomiting. Pt has been exposed to coronavirus recently via family members. Pt is vaccinated against coronavirus x 2 in April 2021 with pfizer vaccine. Pt notes chronic headache and neuropathy pain from shingles outbreak from 2 years ago. Pt denies fever, chills, sinus pressure, rhinorrhea, purulent sputum, abdominal pain, diarrhea, constipation or dysuria.
Pt. has redness on half the arm. Slightly warm to touch. Vaccine administered 6 days ago.
red spots on face, chest and arm; constant burning under the skin; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (red spots on face, chest and arm) and SKIN BURNING SENSATION (constant burning under the skin) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, the patient experienced ERYTHEMA (red spots on face, chest and arm) and SKIN BURNING SENSATION (constant burning under the skin). At the time of the report, ERYTHEMA (red spots on face, chest and arm) and SKIN BURNING SENSATION (constant burning under the skin) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications was not provided by the reporter.  Treatment information included steroids.   Most recent FOLLOW-UP information incorporated above includes: On 20-May-2021: Follow up received on 20-MAY-2021 included  Event outcome updated.
About t25 minutes after receiving second shot, my right hip replacement area became very painful.  It was difficult to walk for a few hours.  The next day I could walk but entire hip area was painful.; About t25 minutes after receiving second shot, my right hip replacement area became very painful.  It was difficult to walk for a few hours.  The next day I could walk but entire hip area was painful.; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 05May2021 at 12:15 (at the age of 69-year-old), as a single dose for COVID-19 immunisation. Medical history included blood pressure high. The patient did not have any known allergies. Concomitant medications were unspecified. The patient also received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on an unknown date in 2021 (at the age of 69-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 05May2021 at 12:45, the patient experienced about 25 minutes after receiving second shot, her right hip replacement area became very painful.  It was difficult to walk for a few hours.  The next day the patient could walk but entire hip area was painful. The adverse events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the events pain in hip (right hip replacement area) and walking difficulty was recovering.   No follow-up attempts are possible; Information on lot/batch number has been requested.
Patient describes experiencing pain with the injection followed by a very sore left deltoid for three days. After that it improved and was only painful when she poked at the site. On 10/25/2018 she felt felt severe pain in left deltoid when she reached laterally to pick up papers. The left upper arm has been painful ever since that date.
She is vaccinated with Pfizer vaccine, tested positive for Covid.; She is vaccinated with Pfizer vaccine, tested positive for Covid.; She had a tickle in her throat yesterday; received booster on Dec 6; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). A 53 year-old female patient received bnt162b2 (BNT162B2), administration date 06Dec2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose:1), for COVID-19 immunization, reaction(s): "Covid-19", "Drug ineffective"; Bnt162b2 (Dose:2), for COVID-19 immunization, reaction(s): "covid-19", "Drug ineffective". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 16Dec2021, outcome "unknown" and all described as "She is vaccinated with Pfizer vaccine, tested positive for Covid."; IMMUNISATION (non-serious) with onset 06Dec2021, outcome "unknown", described as "received booster on Dec 6"; THROAT IRRITATION (non-serious) with onset 15Dec2021, outcome "unknown", described as "She had a tickle in her throat yesterday". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (16Dec2021) positive, notes: took the rapid test today and it came back positive. The reporter stated that the patient "is vaccinated with Pfizer vaccine and received booster on 06Dec2021. She had a tickle in her throat yesterday, and took the rapid test today and it came back positive".  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101809561 same reporter/patient/product, different dose/event.
Vaccine brand other=Moderna; COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 42-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), in left arm and as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "high blood pressure" (unspecified if ongoing), notes: Treated for high blood pressure; "Post-traumatic stress disorder" (unspecified if ongoing). Concomitant medication(s) included: LOSARTIN; PAROXETINE. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Sep2022, outcome "not recovered" and all described as "COVID-19"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "Vaccine brand other=Moderna". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: negative, notes: 5 days after negative test. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report as received from a medical assistant refers to an unspecified patients of unknown ages and genders who on an unknown dates were vaccinated with two improperly stored doses of VARIVAX (Merck) (dose, lot #, expiration date and route were not reported). No adverse events were reported. It was unknown if the patients sought medical attention. This is one of several reports from the same source. Additional information has been requested.
weakness, rapid heart rate, and panic five minutes after receiving vaccine. went away on its own after a couple of minutes swelling and soreness of axillary lymph nodes five days after the vaccine, currently ongoing
3/2/17 arm swelling, redness and streaking down her arm from injection site. Malaise, nausea & redness for 4-5 days. 3/13/12 limited upper right hand, elbow pain, can't lay on that arm. She has hypersensitive pain to touch down to forearm.
Tues no symptoms. Wed 20th soreness in left arm, nausea. Thursday- nausea , chills, migraine. Friday- ringing in left ear, nausea, hot flashes.  Saturday- louder ringing in left ear, nausea, headache, extreme dizziness, loss of balance
This spontaneous report as received from a other health professional refers to a male patient of unknown age. On an unknown date the patient was vaccinated with ZOSTAVAX, 19400 DF, subcutaneous for prophylaxis. On an unknown date the patient experienced herpes zoster. The outcome of herpes zoster is unknown. This is one of two reports received from the same reporter.; Sender's Comments: US-009507513-1708USA005392:
Temp max 101.8, left axilla lymph node swelling and pain, left clavicular lymph node swelling and pain, headache, chills, body aches. lasting from 0100 1/19/2021until 0900 1/20/2021
Sweating started approximately 10 hours after receiving the second dose. Took 2 Tylenol in the evening 6April21. The following day a fever up to 101.2 at noon on 7April2021. Took 2 Tylenol at 5 am 7April21 and 2 more Tylenol at noon 7April21.
Patient was in bed until night; Received a vaccine that is past the suggested used by date; Soreness at the site of injection; Overpowering headache in the afternoon and it went downhill from there; Very high level of body ache from head to toe; Feeling nauseous; Feels like having a flu but not stomach flu; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Feels like having a flu but not stomach flu), SOMNOLENCE (Patient was in bed until night), EXPIRED PRODUCT ADMINISTERED (Received a vaccine that is past the suggested used by date), VACCINATION SITE PAIN (Soreness at the site of injection) and HEADACHE (Overpowering headache in the afternoon and it went downhill from there) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 049C21A and 003C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jun-2021, the patient experienced INFLUENZA LIKE ILLNESS (Feels like having a flu but not stomach flu), EXPIRED PRODUCT ADMINISTERED (Received a vaccine that is past the suggested used by date), VACCINATION SITE PAIN (Soreness at the site of injection), HEADACHE (Overpowering headache in the afternoon and it went downhill from there), MYALGIA (Very high level of body ache from head to toe) and NAUSEA (Feeling nauseous). On an unknown date, the patient experienced SOMNOLENCE (Patient was in bed until night). The patient was treated with NAPROXEN SODIUM (ALEVE) at a dose of Aleve 2 tablets and IBUPROFEN at a dose of Ibuprofen 2 tablets. At the time of the report, INFLUENZA LIKE ILLNESS (Feels like having a flu but not stomach flu), SOMNOLENCE (Patient was in bed until night), VACCINATION SITE PAIN (Soreness at the site of injection), HEADACHE (Overpowering headache in the afternoon and it went downhill from there), MYALGIA (Very high level of body ache from head to toe) and NAUSEA (Feeling nauseous) outcome was unknown and EXPIRED PRODUCT ADMINISTERED (Received a vaccine that is past the suggested used by date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient received both scheduled doses of mRNA-1273 prior to the events, therefore action taken with the drug in response to the events was not applicable.  Concomitant product use was not provided by the reporter.
10/25/02 TC from mom child with 2 x 1 red area at site of MMR injection, Eyes watery and puffy Treating with Tylenol , cold packs; RN instructs could be mild case of measles, Treating sx appropriately keep child inside at home and call MD or Er if symptoms not manageable.
large, swollen, reddened area. Patient states - painful; Site examined by Dr recommended warm compress and antihistamines.
Muscle aches strong enough that I took a long hot shower and painkillers. Fever. Immediate full body shivering when I got out of bed. Very tired. Recovered within 16 hours.
No adverse event; The patient was administered with improperly stored VAQTA; This spontaneous report was received from a certified medical assistant (CMA) referring to a 13-month-old male patient.  No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant medications was provided.  On 23-OCT-2019, the patient was vaccinated with improperly stored hepatitis a vaccine, inactivated (VAQTA) (lot # S007770, expiration date: 24-JUL-2020, strength, dose number, anatomical location and route of administration were not reported) for prophylaxis (product storage error). It was reported that the vaccine was exposed to the temperature above 47 degrees Fahrenheit/9 degree Celsius (9.3 Celsius) for 23 minutes. The previous temperature excursion were at the temperature above 47 degrees Fahrenheit/9 degree Celsius (10.7 Celsius) for 33 minutes, at the temperature above 47 degrees Fahrenheit/9 degree Celsius (8.7 Celsius) for 36 minutes, at the temperature above 47 degrees Fahrenheit/9 degree Celsius (8.9 Celsius) for 15 minutes and at the temperature above 47 degrees Fahrenheit/9 degree Celsius (9 Celsius) for 12 minutes. The call was because of a data logger. No adverse event was reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S007770; expirationdate: 24-JUL-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-1910USA012749:
EngerixB 1st dose 20Aug2014, no further doses given; Havirx 1st dose 20Aug2014, 2nd dose 12Apr2022; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 72-year-old male patient who received HAV (Havrix) for prophylaxis.   Co-suspect products included HBV (Engerix B) for prophylaxis.   Previously administered products included Havrix (received 1st dose on 20th August 2014, batch number 793JR) and Engerix B (received 1st dose on 20th August 2014, batch number B3744L).   On 12th April 2022, the patient received the 2nd dose of Havrix. On an unknown date, the patient did not receive the 2nd dose of Engerix B. On 12th April 2022, unknown after receiving Havrix and not applicable after receiving Engerix B, the patient experienced drug dose administration interval too long. On an unknown date, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the drug dose administration interval too long and incomplete course of vaccination were unknown.   Additional Information: GSK Receipt Date: 13-APR-2022 Reporter's Comments:  On 12th April 2022 the patient received a second dose of Havrix but the patient had not received any further doses of Engerix B. The reporter did not consent to follow up. Additional Supportive Information: The patient received 2nd dose of Havrix later than the recommended interval, which led to lengthening of vaccination schedule. Till the time of reporting, the patient did not receive 2nd dose of Engerix B, which led to incomplete course of vaccination.
Reproductive adverse event following the last doses of AVA. Severe pain in arm/back/neck following the last two doses of AVA. Symptoms began within a few hours of the immunizations.
got his 1st dose on 27Mar2021 and then got Covid; got his 1st dose on 27Mar2021 and then got Covid; This is a spontaneous report from a contactable consumer (patient) from a Pfizer-sponsored program. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 27Mar2021 (Batch/Lot number was not reported) as 1st dose, single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient got his 1st dose on 27Mar2021 and then got Covid on an unspecified date. His 2nd dose was supposed to be on 07Apr2021 and when he got Covid he ended up in the hospital and is now out and wanted to know when he can get the 2nd dose. The outcome of the events was unknown.  Information on the batch/lot number has been requested.
Patient is a 66-year-old male with a past medical history significant for hypertension, diabetes, myocardial infarction ×4 with AICD who presents to our facility today for syncopal episode. Patient states he was sitting in his chair when he developed midline back pain, diaphoresis. Patient states he stood up in the attempt to walk to his bed and lost consciousness. Patient was found on the floor by his grandson. Patient states he has not been feeling well past couple days and was at our facility last night where he tested positive for coronavirus. Patient otherwise endorses forehead pain where he has an abrasion. She denies any fevers, chills, cough, sore throat, chest pain, shortness of breath, abdominal pain, nausea, vomiting, diarrhea nor urinary symptoms.  Covid-19 Vaccine (Pfizer)             01/27/2021  02/17/2021
Red and elevated area on left deltoid. Increased warmth at site of MENACTRA injection.
RED, PAINFULL, HOT, SWOLLEN X 4 DAYS ALL AROUND INJECTION SITE AND MOST OF UPPER ARM.  PATIENT TOOK TYLENOL FOR PAIN.